<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134010">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01357161</url>
  </required_header>
  <id_info>
    <org_study_id>1775-004</org_study_id>
    <nct_id>NCT01357161</nct_id>
  </id_info>
  <brief_title>A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)</brief_title>
  <official_title>A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the safety and efficacy of MK-1775 in combination with paclitaxel +
      carboplatin in the treatment of ovarian, fallopian tube, and primary peritoneal tumors with
      the P53 mutation. In Part 1, a small group of participants will receive MK-1775 along with
      paclitaxel and carboplatin to find the maximum tolerable MK-1775 dose for this combination.
      Pharmacokinetics will also be assessed during this period. In Part 2, participants will be
      randomly assigned to receive either MK-1775 + paclitaxel + carboplatin or placebo +
      paclitaxel + carboplatin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Imaging will be performed every 6 weeks from the start date of study therapy until documentation of progression or death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Imaging will be performed every 6 weeks from the start date of study therapy until documentation of progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization (baseline) to death due to any cause</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>MK-1775 + paclitaxel + carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + paclitaxel + carboplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1775</intervention_name>
    <description>MK-1775 capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle</description>
    <arm_group_label>MK-1775 + paclitaxel + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to MK-1775, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle</description>
    <arm_group_label>Placebo + paclitaxel + carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle</description>
    <arm_group_label>MK-1775 + paclitaxel + carboplatin</arm_group_label>
    <arm_group_label>Placebo + paclitaxel + carboplatin</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin, IV infusion on Day 1 of each 3-week cycle</description>
    <arm_group_label>MK-1775 + paclitaxel + carboplatin</arm_group_label>
    <arm_group_label>Placebo + paclitaxel + carboplatin</arm_group_label>
    <other_name>paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-low grade, non-borderline (low malignant potential)
             ovarian, fallopian tube, or primary peritoneal cancer which has progressed after
             paclitaxel / platinum-based therapy.

          -  Platinum-sensitive disease. Radiological progression must have occurred 6 months or
             more after the completion of the most recent platinum-based treatment.

          -  Measurable disease.

          -  Available tumor sample(s).

          -  Performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG) Performance
             Scale.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Pregnancy or the intention to become pregnant during the course of the study.

          -  Participation in a study with an investigational compound or device within 28 days of
             receiving first dose of study medication.

          -  Active central nervous system (CNS) metastases and/or carcinomatous meningitis.

          -  Primary CNS tumor.

          -  Known hypersensitivity or contraindications to the components of potential study
             therapy (paclitaxel, carboplatin, MK-1775) or its analogs (i.e. cremophor, mannitol,
             etc.).

          -  Participant requires the use of medications or products that are metabolized by, or
             inhibit, or induce Cytochrome P450 3A (CYP3A4).

          -  Ongoing peripheral neuropathies ≥Grade 2 and related to previous treatment.

          -  Known psychiatric or substance abuse disorders.

          -  Regular use (including &quot;recreational use&quot;) of any illicit drugs or recent history
             (within the last year) of drug or alcohol abuse.

          -  HIV positive.

          -  Active Hepatitis B or C.

          -  Symptomatic ascites or pleural effusion.

          -  Clinical history suggestive of Li Fraumeni Syndrome.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 24, 2016</lastchanged_date>
  <firstreceived_date>May 18, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
